Contact
Please use this form to send email to PR contact of this press release:
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
TO:
Please use this form to send email to PR contact of this press release:
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
TO: